Mark N Gaze

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma
    M N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Q J Nucl Med Mol Imaging 57:66-78. 2013
  2. doi request reprint Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: a SIOPEN study
    Mark N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    Int J Radiat Oncol Biol Phys 85:170-4. 2013
  3. doi request reprint Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study
    Mark N Gaze
    Department of Oncology, University College London Hospital, UK
    Radiother Oncol 97:593-5. 2010
  4. doi request reprint 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    J Nucl Med 52:1041-7. 2011
  5. doi request reprint Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, First Floor Central, 250 Euston Road, London NW1 2PG, UK
    Future Oncol 9:439-49. 2013
  6. doi request reprint Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
    Michael A Kosmin
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Eur J Nucl Med Mol Imaging 39:597-601. 2012
  7. doi request reprint Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy
    Valerie Said-Conti
    Department of Paediatric Nephrology, Great Ormond Street Hospital NHS Trust, London, UK
    Pediatr Nephrol 28:2053-6. 2013
  8. doi request reprint 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis
    Nikolaos D Papathanasiou
    Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom
    J Nucl Med 52:519-25. 2011

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma
    M N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Q J Nucl Med Mol Imaging 57:66-78. 2013
    ..Only in this way will it be possible for [131I]-mIBG to be used to its best advantage in the complex multimodality treatment schedules required for high-risk neuroblastoma...
  2. doi request reprint Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: a SIOPEN study
    Mark N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    Int J Radiat Oncol Biol Phys 85:170-4. 2013
    ..This study reviewed the compliance of plans with the radiation therapy guidelines of the International Society of Paediatric Oncology (Europe) Neuroblastoma Group (SIOPEN) High-Risk Trial protocol...
  3. doi request reprint Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study
    Mark N Gaze
    Department of Oncology, University College London Hospital, UK
    Radiother Oncol 97:593-5. 2010
    ..This will enable investigation of the relationship between radiotherapy quality and local control...
  4. doi request reprint 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    J Nucl Med 52:1041-7. 2011
    ....
  5. doi request reprint Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, First Floor Central, 250 Euston Road, London NW1 2PG, UK
    Future Oncol 9:439-49. 2013
    ..001). IMAT would have enabled delivery of the full protocol dose in eight out of ten protocol-noncompliant patients. IMAT may improve outcomes through improved protocol compliance and better dose distributions...
  6. doi request reprint Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
    Michael A Kosmin
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Eur J Nucl Med Mol Imaging 39:597-601. 2012
    ..In this study we audited BP changes in patients receiving (131)I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors...
  7. doi request reprint Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy
    Valerie Said-Conti
    Department of Paediatric Nephrology, Great Ormond Street Hospital NHS Trust, London, UK
    Pediatr Nephrol 28:2053-6. 2013
    ..The modalities of treatment include reduction in immunosuppression, cranial radiotherapy (CRT), intravenous and intrathecal rituximab when CD20 is expressed on B-lymphocytes and PTLD cells, and chemotherapy...
  8. doi request reprint 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis
    Nikolaos D Papathanasiou
    Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom
    J Nucl Med 52:519-25. 2011
    ..The aim of our study was to evaluate prospectively the diagnostic performance and prognostic significance of (18)F-FDG PET/CT in comparison with (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging in patients with high-risk neuroblastoma...